PReS-FINAL-2134: Assessment of radiographic progression in patients (pts) with systemic juvenile idiopathic arthritis (sjia) treated with tocilizumab (TCZ): 2-year results from the tender trial

被引：0
|
作者：
C Malattia
N Ruperto
E Palmisani
S Pederzoli
A Pistorio
HI Brunner
R Cuttica
I Calvo
SM Garay
D Eleftheriou
C Wouters
J Wang
C Devlin
D Lovell
A Martini
F De Benedetti
A Ravelli
机构：
[1] PRINTO,
[2] PRCSG,undefined
[3] Roche,undefined
[4] IRCCS Ospedale Ped Bambino Gesu,undefined
来源：
Pediatric Rheumatology | / 11卷 / Suppl 2期
关键词：
Juvenile Idiopathic Arthritis; Score Change; Median Change; Tocilizumab; Radiographic Progression;
D O I：
10.1186/1546-0096-11-S2-P147
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 10 条
  • [1] Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (sJIA): TENDER 52-week data
    Fabrizio De Benedetti
    Hermine Brunner
    Nicola Ruperto
    R Cuttica
    Clara Malattia
    Rayfel Schneider
    Patricia Woo
    Despina Eleftheriou
    Eileen Baildam
    Ruben Burgos-Vargas
    Pavla Dolezalova
    Stella M Garay
    Rik Joos
    Nico Wulffraat
    Zbyszek Zuber
    Francesco Zulian
    Carine Wouters
    Ricardo M Xavier
    Lawrence Zemel
    Stephen Wright
    Andy Kenwright
    Alberto Martini
    Daniel Lovell
    Pediatric Rheumatology, 10 (Suppl 1)
  • [2] Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (SJIA): tender 52-week data
    F De Benedetti
    H Brunner
    N Ruperto
    R Schneider
    P Woo
    R Burgos-Vargas
    P Dolezalova
    R Joos
    N Wulffraat
    Z Zuber
    F Zulian
    R Allen
    D Brown
    J Chaitow
    M Pardeo
    G Espada
    B Flato
    V Gerloni
    G Horneff
    S Wright
    A Kenwright
    D Lovell
    A Martini
    Pediatric Rheumatology, 9 (Suppl 1)
  • [3] PReS-FINAL-2180: Efficacy and safety of tocilizumab (TCZ) in patients with polyarticular-course juvenile idiopathic arthritis (pcJIA): 2-year data from CHERISH
    F De Benedetti
    N Ruperto
    Z Zuber
    R Cuttica
    R Xavier
    I Calvo
    N Rubio
    E Alekseeva
    V Chasnyk
    J Chavez
    G Horneff
    V Opoka-Winiarska
    P Quartier
    A Spindler
    C Keane
    K Bharucha
    J Wang
    D Lovell
    A Martini
    HI Brunner
    Pediatric Rheumatology, 11 (Suppl 2)
  • [4] Tapering and withdrawal of tocilizumab in patients with systemic juvenile idiopathic arthritis in inactive disease: results from an alternative dosing regimen in the TENDER study
    F De Benedetti
    N Ruperto
    H Brunner
    A Grom
    N Wulffraat
    M Henrickson
    R Jerath
    Y Kimura
    AK Kadva
    J Wang
    A Martini
    D Lovell
    Pediatric Rheumatology, 12 (Suppl 1)
  • [5] Tocilizumab may slow radiographic progression in patients with systemic or polyarticular-course juvenile idiopathic arthritis: post hoc radiographic analysis from two randomized controlled trials
    Malattia, Clara
    Ruperto, Nicolino
    Pederzoli, Silvia
    Palmisani, Elena
    Pistorio, Angela
    Wouters, Carine
    Dolezalova, Pavla
    Flato, Berit
    Garay, Stella
    Giancane, Gabriella
    Wells, Chris
    Douglass, Wendy
    Brunner, Hermine I.
    De Benedetti, Fabrizio
    Ravelli, Angelo
    ARTHRITIS RESEARCH & THERAPY, 2020, 22 (01)
  • [6] Tocilizumab may slow radiographic progression in patients with systemic or polyarticular-course juvenile idiopathic arthritis: post hoc radiographic analysis from two randomized controlled trials
    Clara Malattia
    Nicolino Ruperto
    Silvia Pederzoli
    Elena Palmisani
    Angela Pistorio
    Carine Wouters
    Pavla Dolezalova
    Berit Flato
    Stella Garay
    Gabriella Giancane
    Chris Wells
    Wendy Douglass
    Hermine I. Brunner
    Fabrizio De Benedetti
    Angelo Ravelli
    Arthritis Research & Therapy, 22
  • [7] Growth During Tocilizumab Therapy for Polyarticular-course Juvenile Idiopathic Arthritis: 2-year Data from a Phase III Clinical Trial
    Bharucha, Kamal N.
    Brunner, Hermine I.
    Calvo Penades, Inmaculada
    Nikishina, Irina
    Rubio-Perez, Nadina
    Oliveira, Sheila
    Kobusinska, Katarzyna
    Schmeling, Heinrike
    Sztajnbok, Flavio
    Weller-Heinemann, Frank
    Zholobova, Elena
    Zulian, Francesco
    Allen, Roger
    Chaitow, Jeffrey
    Frane, James
    Wells, Chris
    Ruperto, Nicolino
    De Benedetti, Fabrizio
    JOURNAL OF RHEUMATOLOGY, 2018, 45 (08) : 1173 - 1179
  • [8] Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan
    Yokota, Shumpei
    Itoh, Yasuhiko
    Morio, Tomohiro
    Origasa, Hideki
    Sumitomo, Naokata
    Tomobe, Minako
    Tanaka, Kunihiko
    Minota, Seiji
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 (09) : 1654 - 1660
  • [9] Intravenous dosing of tocilizumab in patients younger than two years of age with systemic juvenile idiopathic arthritis: results from an open-label phase 1 clinical trial
    Mallalieu, Navita L.
    Wimalasundera, Sunethra
    Hsu, Joy C.
    Douglass, Wendy
    Wells, Chris
    Penades, Inmaculada Calvo
    Cuttica, Ruben
    Huppertz, Hans-Iko
    Joos, Rik
    Kimura, Yukiko
    Milojevic, Diana
    Rosenkranz, Margalit
    Schikler, Kenneth
    Constantin, Tamas
    Wouters, Carine
    PEDIATRIC RHEUMATOLOGY, 2019, 17 (01)
  • [10] Intravenous dosing of tocilizumab in patients younger than two years of age with systemic juvenile idiopathic arthritis: results from an open-label phase 1 clinical trial
    Navita L. Mallalieu
    Sunethra Wimalasundera
    Joy C. Hsu
    Wendy Douglass
    Chris Wells
    Inmaculada Calvo Penades
    Ruben Cuttica
    Hans-Iko Huppertz
    Rik Joos
    Yukiko Kimura
    Diana Milojevic
    Margalit Rosenkranz
    Kenneth Schikler
    Tamas Constantin
    Carine Wouters
    Pediatric Rheumatology, 17
1